Does the Use of Antidepressants Accelerate the Disease Progress in Creutzfeldt–Jakob Disease Patients With Depression? A Case Report and A Systematic Review

Liang, Yifan; Yan, Li; Wang, Huibin; Cheng, Xi; Guan, Meiting; Zhong, Shanshan; Zhao, Chuansheng

doi:10.3389/fpsyt.2019.00297

Cited by 4 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is subdivided into four subtypes: sporadic (sCJD), familial (fCJD), variant (vCJD), and iatrogenic (iCJD). The annual global incidence of CJD is 1 to 2 cases per 1 million population, and sCJD accounts for the majority (approximately 85% of CJD cases) [ 1 ]. The distinctive clinical picture includes intellectual disability, myoclonus, visual or cerebellar abnormalities, pyramidal or extrapyramidal signs, and akinetic mutism.…”

Section: Introductionmentioning

confidence: 99%

Misdiagnosis of rarest subtype of sporadic Creutzfeldt Jakob Disease: a case report

et al. 2023

View full text Add to dashboard Cite

Background Creutzfeldt–Jakob disease (CJD), is a deadly degenerative condition of the central nervous system marked by rapidly progressive dementia. Magnetic resonance imaging (MRI) abnormalities in the cerebral cortex, basal ganglia, thalamus, and cerebellum could indicate severe acute diseases caused by a variety of factors. Although their MRI patterns may resemble those of CJD, clinical history, additional MRI findings, and laboratory testing are all necessary to provide a reliable difference. Here, we report a misdiagnosed case of probable VV1 subtype of sporadic CJD (sCJD) in which follow-up MRI supported the diagnosis. Case presentation A 41-year-old male patient attended the Neuropsychiatry Department with rapidly progressive dementia, akinetic mutism, and difficulty walking and speaking. His problem began with forgetfulness, disorganized behavior, and disorganized speech 7 months earlier which progressed rapidly and was accompanied by aphasia, apraxia, agnosia, and akinetic mutism in the last 2 months. On neurologic examination, hypertonia, hyperreflexia, frontal ataxia, bradykinesia, gait apraxia, and aphasia were noted. Based on clinical features and rapid symptoms progression the likely diagnosis of CJD was suspected. MRI and electroencephalography (EEG) were advised. MRI revealed features of diffuse cortical injury of both cerebral hemispheres also involving bilateral corpus striatum with evidence of cerebral volume loss. EEG showed lateralized periodic theta slow waves on the right side. According to the CDC’s diagnostic criteria for CJD, the diagnosis of probable sCJD was established. Supportive care and symptomatic treatment are provided for the patient. After a 1-month follow up the patient’s condition deteriorated significantly. The time-lapse from the first reported symptom to death was about 13 months. Conclusion The need of addressing CJD in patients presenting with rapidly progressive dementia is highlighted in this case report. In the early stages of the disease, interpretation of MRI results might cause diagnostic difficulties; therefore, follow-up MRI is critical in obtaining the correct diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Misdiagnosis of rarest subtype of sporadic Creutzfeldt Jakob Disease: a case report

et al. 2023

View full text Add to dashboard Cite

show abstract

Sertraline/venlafaxine

2019

Reactions Weekly

View full text Add to dashboard Cite

Prion diseases motor and neuropsychiatric symptom cluster pharmacotherapy: structured scoping review

Hogg,

Centola,

McDermott

et al. 2024

BMJ Support Palliat Care

View full text Add to dashboard Cite

BackgroundPrion diseases are a group of rare, neurodegenerative conditions that are invariably fatal and cause a variety of symptoms, which can prove challenging to control. Through this paper, we aim to review the current evidence regarding pharmacological management of neuropsychiatric and motor symptoms of prion disease as well as draw on experts’ and relatives’ experience, to evaluate the current evidence and provide recommendations moving forwards.MethodsA scoping review of the literature for pharmacological management of symptoms was conducted using the systematic review tool, COVIDENCE, with searches conducted through four databases. 120 papers were selected for inclusion, and data extraction was carried out by two independent reviewers. Given the lack of high-quality data and small numbers, no further attempt at statistical analysis was made, and results are presented in a thematic synthesis.ResultsAlthough a broad range of approaches and pharmacotherapies are trialled to manage these challenging symptoms, there are patterns emerging of some efficacy seen with the use of benzodiazepines, antipsychotic and anticonvulsant medications in both motor and neuropsychiatric symptoms in prion disease. These approaches and associated challenges were reflected in international expert opinion that was gathered via online survey.ConclusionThere continues to be a paucity of good-quality evidence and we suggest a need for longitudinal, population-based and standardised research to allow a robust evidence base, which in turn will guide excellent symptom control and end of life care for this group of complex patients.

show abstract

Does the Use of Antidepressants Accelerate the Disease Progress in Creutzfeldt–Jakob Disease Patients With Depression? A Case Report and A Systematic Review

Cited by 4 publications

References 50 publications

Misdiagnosis of rarest subtype of sporadic Creutzfeldt Jakob Disease: a case report

Misdiagnosis of rarest subtype of sporadic Creutzfeldt Jakob Disease: a case report

Sertraline/venlafaxine

Prion diseases motor and neuropsychiatric symptom cluster pharmacotherapy: structured scoping review

Contact Info

Product

Resources

About